Heparan sulfate proteoglycan-collagen type I interaction site (HSPG-COL1 site)

The interaction between Heparan Sulfate Proteoglycans (HSPGs) and specific heparin-binding sites on Collagen Type I is a fundamental regulatory mechanism within the extracellular matrix (ECM). HSPGs, such as syndecans and perlecan, bind to cationic residues on the collagen triple helix, a process essential for the proper assembly and stabilization of collagen fibrils (San Antonio et al., 1994, J Cell Biol). This binding site also functions as a critical reservoir for various growth factors, including Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF), thereby controlling their local concentration and signaling activity (UniProt P02452). In pathological conditions such as chronic fibrosis or tumor progression, the dysregulation of this interaction can lead to aberrant tissue stiffness and enhanced cellular migration. Therapeutic targeting of these sites using heparin mimetics or competitive peptides aims to modulate ECM remodeling and inhibit the signaling pathways that drive disease progression (PubMed PMID: 8144557). Consequently, this interaction site represents a specialized target for drug development in regenerative medicine and oncology.

Other names

Heparin-binding site on Collagen IHSPG-Collagen I binding domainCollagen type I heparin-binding siteHeparin-binding site on Collagen alpha-1(I) chain

Competitive inhibition of the interaction between heparan sulfate proteoglycans and collagen type I to modulate fibril formation, stabilize the extracellular matrix, and regulate the bioavailability of heparin-binding growth factors.